Our Core Bio-Sensing Technology Consists of Three Major Components:
Using raman technology to digitize bodily fluid.
Molecular fingerprinting to quantify results.
Proprietary machine learning algorithms.
Our Basic Process
Kaligia Biosciences’ Point of Care Technology
Kaligia Biosciences’ technology is based on in-vitro point-of-care devices, statistics-based algorithms, and analytics.
Product and Technology Development
Kaligia’s RBA device is in various stages of research and approval.
Rapid Biofluid Analyzer (RBA)
RBA is an in-vitro measurement device which is invasive for blood application and non-invasive for other bodily fluids such as saliva, urine and sweat. This lends to numerous potential applications in the biomedical field.
Whole Blood Hemoglobin Test
– Hemoglobin (Hgb), Hematocrit (HCT), and Red Blood Cells (RBC)
COVID Rapid Screener
– Glucose, Creatinine, Triglycerides, Cholesterol, Albumin, Total Protein
Serum (in R&D)
– COVID-19, Influenza A, Influenza B
Urine (in R&D)
- Portable Lab
- Optimized for Operator Safety
- Significantly decreased risk for contamination
- Results in under 3 minutes
Never Stop Learning
Kaligia Biosciences’ Acquisition Software and Analytics
Kaligia Biosciences employs statistics-based algorithms to calculate quantitative results on biofluid composition. These proprietary algorithms are continuously being improved upon as more research is conducted within our CLIA-certified laboratory.